A detailed history of Royal Bank Of Canada transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 25,848 shares of VYGR stock, worth $149,401. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,848
Previous 25,727 0.47%
Holding current value
$149,401
Previous $203,000 25.62%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.77 - $9.27 $698 - $1,121
121 Added 0.47%
25,848 $151,000
Q2 2024

Aug 14, 2024

BUY
$7.42 - $10.54 $25,561 - $36,310
3,445 Added 15.46%
25,727 $203,000
Q1 2024

Nov 05, 2024

SELL
$7.15 - $10.84 $24,631 - $37,343
-3,445 Reduced 13.39%
22,282 $207,000
Q1 2024

May 15, 2024

BUY
$7.15 - $10.84 $73,394 - $111,272
10,265 Added 85.42%
22,282 $207,000
Q4 2023

Feb 14, 2024

BUY
$6.28 - $8.81 $34,791 - $48,807
5,540 Added 85.53%
12,017 $101,000
Q3 2023

Nov 14, 2023

SELL
$7.55 - $11.25 $41,487 - $61,818
-5,495 Reduced 45.9%
6,477 $50,000
Q2 2023

Aug 14, 2023

SELL
$6.94 - $13.99 $242 - $489
-35 Reduced 0.29%
11,972 $137,000
Q1 2023

May 15, 2023

SELL
$6.0 - $10.78 $1,284 - $2,306
-214 Reduced 1.75%
12,007 $92,000
Q4 2022

Feb 14, 2023

BUY
$4.94 - $6.61 $1,071 - $1,434
217 Added 1.81%
12,221 $74,000
Q3 2022

Nov 14, 2022

BUY
$5.57 - $7.47 $63,241 - $84,814
11,354 Added 1746.77%
12,004 $71,000
Q3 2021

Nov 15, 2021

SELL
$2.63 - $4.12 $13,904 - $21,782
-5,287 Reduced 89.05%
650 $2,000
Q2 2021

Aug 16, 2021

BUY
$3.94 - $5.44 $23,391 - $32,297
5,937 New
5,937 $25,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $223M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.